MedTrace Logo

123I-ALTROPANE® Reference Image Acquisition in Subjects With Diagnostically Uncertain Tremor

NCT00596908 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 54

Last updated 2009-05-29

No results posted yet for this study

Summary

This study is designed to obtain an imaging training set that will be used to evaluate images in future trials. Currently, no radiopharmaceutical diagnostic imaging agent has been approved by the FDA in the U.S. for use in diagnosing Parkinson disease and related Parkinsonian syndromes. The diagnosis of Parkinsonian syndromes in the U.S. is based on clinical criteria only. The goal is to demonstrate that 123I-ALTROPANE® paired with SPECT imaging permits a more accurate early diagnosis of Parkinson disease than a clinical diagnosis by a general neurologist.

Conditions

  • Upper Extremity Tremor

Sponsors & Collaborators

  • Alseres Pharmaceuticals, Inc

    lead INDUSTRY

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Completion
2009-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00596908 on ClinicalTrials.gov